Evidence map›Paper›PMID 41781328›Full record

ArticleClinical and translational science2026

Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer Patients.

Julia Suchomel, Christine M Bowman, Po-Chang Chiang, Mallika Dhawan, Jennifer Eng-Wong, Paloma Hauser, Ryan Johnson, Ariel R Muliadi, Swathi Pisupati, Vidya Ramakrishnan and 2 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julia SuchomelGenentech, Inc., South San Francisco, California, USA.ORCID 0009-0003-0101-421X
Christine M BowmanGenentech, Inc., South San Francisco, California, USA.
Po-Chang ChiangGenentech, Inc., South San Francisco, California, USA.
Mallika DhawanGenentech, Inc., South San Francisco, California, USA.
Jennifer Eng-WongGenentech, Inc., South San Francisco, California, USA.
Paloma HauserGenentech, Inc., South San Francisco, California, USA.
Ryan JohnsonGenentech, Inc., South San Francisco, California, USA.
Ariel R MuliadiGenentech, Inc., South San Francisco, California, USA.
Swathi PisupatiGenentech, Inc., South San Francisco, California, USA.
Vidya RamakrishnanGenentech, Inc., South San Francisco, California, USA.
Leonie WagnerF. Hoffmann-La Roche, Basel, Switzerland.
Sandhya V MandlekarGenentech, Inc., South San Francisco, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migoprotafib is a potent and selective inhibitor of Src homology-2 domain-containing phosphatase 2 (SHP2) under investigation in Phase I (PhI) trials both as monotherapy and in combination with multiple therapies for patients with metastatic solid tumors. The PhI study reported herein aimed to assess both a new tablet formulation and the impact of a high-fat meal on the pharmacokinetics (PK) of migoprotafib at the recommended Phase II dose (RP2D) of 60 mg in patients. In two distinct cohorts, patients were administered migoprotafib as a tablet or capsule formulation to assess the impact of formulation, or as a tablet under fasted or fed conditions to assess the impact of food. In an evaluation of the effect of formulation in 20 subjects, the geometric mean ratios (GMRs) [90% CI] of the tablet: capsule formulation were 101 [89.8-114], and 103 [86.2-122], for AUC

Indexed as

Antineoplastic AgentsFood-Drug InteractionsNeoplasmsAdultAgedArea Under CurveCapsulesFastingFemaleHumansMaleMiddle AgedTabletsAntineoplastic AgentsCapsulesTabletsabsorptioncancersexposure responseformulationpharmacokinetics

Identifiers

PMID41781328
PMCPMC12960017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.